Enliven Therapeutics prices upsized public offering at $37.50 per share

Enliven Therapeutics Inc. (NASDAQ: ELVN) announced the pricing of its upsized public offering of 8,933,334 shares of common stock at $37.50 per share. The clinical-stage biopharmaceutical company also offered pre-funded warrants to purchase up to 1,733,333 shares at $37.499 per warrant.

The offering is expected to generate gross proceeds of approximately $400 million before deducting underwriting discounts, commissions and other expenses. The transaction is scheduled to close on or about June 15, 2026, subject to customary closing conditions.

Enliven granted underwriters a 30-day option to purchase up to an additional 1.6 million shares at the public offering price, minus underwriting discounts and commissions. The pre-funded warrants are priced at the public offering price less the $0.001 per share exercise price.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays serve as joint book-running managers for the offering. Mizuho acts as a book-running manager and LifeSci Capital as a passive book-running manager. Baird serves as lead manager and Jones as manager.

The offering is conducted under a Registration Statement on Form S-3ASR that became effective upon filing with the Securities and Exchange Commission on August 13, 2025. Enliven filed a preliminary prospectus supplement with the SEC, with a final prospectus supplement to follow.

Enliven focuses on discovering and developing small molecule therapeutics for precision medicine applications. The company is based in Burlingame, California.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• RedHill Biopharma closes $6M private placement with warrant upside
• TaskUs names Rishabh Khemka as CFO, effective June 2026